This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Related Articles

(Circulation. 2006;113:1717.)
© 2006 American Heart Association, Inc.

Issue Highlights

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	PROGRESSION OF PLASMINOGEN ACTIVATOR INHIBITOR-1 AND FIBRINOGEN LEVELS IN RELATION TO INCIDENT TYPE 2 DIABETES, by Festa et al.

 
Several studies have shown that fibrinolytic and coagulation abnormalities predict the incidence of type 2 diabetes. These prior reports used single measurements of biomarkers and did not investigate the possibility that changes in fibrinolytic/coagulation biomarkers are related to the development of diabetes. In this issue of Circulation, Festa and colleagues studied the relations of changes in circulating plasminogen activator inhibitor-1 (PAI-1) and fibrinogen levels to the incidence of diabetes in 843 healthy, nondiabetic participants in the Insulin Resistance Atherosclerosis Study. The investigators noted that baseline and follow-up measurements of PAI-1 and fibrinogen were higher in individuals who developed diabetes compared with levels of these biomarkers in those who did not develop diabetes over the 5-year follow-up period. In multivariable analyses adjusting for other known predictors, change in PAI-1 was related positively to greater odds of developing diabetes, whereas change in fibrinogen was not associated with incident diabetes. These observations raise the possibility that dynamic changes in PAI-1 antedate the development of diabetes. The authors speculate that pharmacological alteration of PAI-1 levels may influence the risk of developing diabetes in high-risk individuals and note that clinical trials would be required to test this premise. See p 1753.

	ASSOCIATION BETWEEN HUMAN FETUIN-A AND THE METABOLIC SYNDROME: DATA FROM THE HEART AND SOUL STUDY, by Ix et al.

 
Fetuin-A is a multifunctional hepatic secretory protein that has complex physiological effects. It inhibits the action of insulin in experimental animals; fetuin-A knockout mice have increased insulin sensitivity and do not gain weight. Fetuin-A also inhibits vascular calcification in experimental studies. In this issue of Circulation, Ix and colleagues evaluated the . . . [Full Text of this Article]

Related Articles:

Atypical Transient Left Ventricular Ballooning Without Involvement of Apical Segment

Pablo Robles, Manuel Alonso, Ana Isabel Huelmos, Jose Julio Jiménez, and Lorenzo López Bescós
Circulation 2006 113: e686-e688. [Extract] [Full Text]

Coronary Artery Spasm

Vinod Raxwal and Kamal Gupta
Circulation 2006 113: e689-e690. [Extract] [Full Text]

Recovery of Left Ventricular Systolic Function After Biventricular Resynchronization Pacing in a Child With Repaired Tetralogy of Fallot and Severe Biventricular Dysfunction

Joel A. Kirsh, Elizabeth A. Stephenson, and Andrew N. Redington
Circulation 2006 113: e691-e692. [Extract] [Full Text]

Letter Regarding Article by Imazio et al, "Colchicine in Addition to Conventional Therapy for Acute Pericarditis" • Response

Antonio Brucato, Yehuda Adler, David H. Spodick, Massimo Imazio, Enrico Cecchi, Daniela Demarie, Brunella Demichelis, Franco Pomari, Mauro Moratti, Gianni Gaschino, Massimo Giammaria, Aldo Ghisio, Riccardo Belli, Rita Trinchero, and Marco Bobbio
Circulation 2006 113: e693-e694. [Extract] [Full Text]

Association Between Human Fetuin-A and the Metabolic Syndrome: Data From the Heart and Soul Study

Joachim H. Ix, Michael G. Shlipak, Vincent M. Brandenburg, Sadia Ali, Markus Ketteler, and Mary A. Whooley
Circulation 2006 113: 1760-1767. [Abstract] [Full Text]

Evidence of a Dominant Backward-Propagating "Suction" Wave Responsible for Diastolic Coronary Filling in Humans, Attenuated in Left Ventricular Hypertrophy

Justin E. Davies, Zachary I. Whinnett, Darrel P. Francis, Charlotte H. Manisty, Jazmin Aguado-Sierra, Keith Willson, Rodney A. Foale, Iqbal S. Malik, Alun D. Hughes, Kim H. Parker, and Jamil Mayet
Circulation 2006 113: 1768-1778. [Abstract] [Full Text]

Progression of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in Relation to Incident Type 2 Diabetes

Andreas Festa, Ken Williams, Russell P. Tracy, Lynne E. Wagenknecht, and Steven M. Haffner
Circulation 2006 113: 1753-1759. [Abstract] [Full Text]